Clinical trials: Oedema
Retinal Vein Occlusion
To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
The purpose of this study is to determine whether Niacin, a B vitamin, may act as a vasodilator to encourage earlier formation of collateral blood vessels that may serve to bypass the obstructed vein in the eye.
- Trial name
- NCT00493064
- Testing
- Nicotinic acid, Prednisolone acetate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Palo Alto Medical Foundation
Diabetic Macular Edema
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Intravitreal injections of pegaptanib every 4 weeks will be efficacious in treating Diabetic Macular Edema (DME), as compared to injections every 6 weeks.
- Trial name
- PRESERVE (NCT01486238)
- Testing
- Macugen® pegaptanib sodium
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Valley Retina Institute
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment…
- Trial name
- RETAIN (NCT01171976)
- Testing
- Ranibizumab
- Where
- 68 sites in Belgium, Czechia and 11 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Cystoid, Vision Disorders
Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
This study is undertaken to determine the effect of intravitreal long acting dexamethasone implant, (Ozurdex®) in improving outcome of cataract surgery in patients with diabetic macular edema.
- Conditions
- Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema, Cystoid Macular Edema Following Cataract Surgery
- Trial name
- NCT01546402
- Testing
- Dexamethasone Drug delivery system (Ozurdex), Cataract surgery
- Where
- India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diabetic Macular Edema
Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial
Purpose: To determine the impact of short-term 4mg/ml dexamethasone solution treatment in diabetic macular edema (DME). Design: Phase II, randomized, prospective, parallel, interventional study.
- Trial name
- EDRMT (NCT03608839)
- Testing
- Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml, Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml, Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Universidade Federal de Pernambuco
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Diabetic Macular Edema
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
A two part, multi-center study consisting of a Phase 1b open label, sequential dose escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating OPT-302 in combination with aflibercept in participants…
- Trial name
- NCT03397264
- Testing
- Aflibercept, OPT-302
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 153 people
- Sponsor
- Opthea Limited
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
- Trial name
- RESOLVE (NCT00284050)
- Testing
- Ranibizumab 0.3 mg, Ranibizumab 0.5 mg
- Where
- Switzerland
- Volunteers
- 151 people
- Sponsor
- Novartis
Edema, Pulmonary, Immersion
Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
This trial is testing the effectiveness of a single oral dose of sildenafil (50 mg) taken 1 hour before a provocative event on the subsequent development of swimming-induced pulmonary edema.
- Conditions
- Edema, Pulmonary, Immersion, Diving
- Trial name
- NCT03686813
- Testing
- Sildenafil Citrate
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Cerebral Edema
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
RATIONALE: Giving the herb Boswellia serrata after surgery and radiation therapy may slow the growth of any remaining tumor cells.
- Trial name
- NCT00243022
- Testing
- Boswellia serrata extract, cyanocobalamin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ali Altunkaya
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular…
- Trial name
- ELARA (NCT06491914)
- Testing
- Aflibercept 8 mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 1,126 people
- Sponsor
- Regeneron Pharmaceuticals
Intracerebral Hemorrhage
Simvastatin For Intracerebral Hemorrhage Study
Study Objective: To analyze if statins are effective in ameliorating perihematomal edema evolution thereby reducing mortality and improving functional outcomes following spontaneous intracerebral hemorrhage (ICH).
- Trial name
- NCT00718328
- Testing
- Simvastatin 80 mg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Heart Failure, Congestive, Edema
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
This drug is being developed to treat cardiac edema. The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in…
- Trial name
- NCT00234104
- Testing
- OPC-41061(Tolvaptan)
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Bone Marrow Edema
Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
The primary aim is to test the reduction of bone marrow edema syndrome after a singular intravenous treatment with Zoledronic Acid within 6 weeks compared to placebo.
- Trial name
- ZoMARS (NCT01348269)
- Testing
- Aclasta
- Where
- 2 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Wuerzburg University Hospital
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
- Trial name
- COBALT (NCT01903720)
- Testing
- dexamethasone implant
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Allergan
Macular Edema, Macular Degeneration
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
The study was designed to assess the efficacy and safety of Lucentis® (ranibizumab 0.5 mg) in diabetic patients presenting with reduced visual acuity due to diabetic macular edema and evaluating spacing out of follow-up after…
- Conditions
- Macular Edema, Macular Degeneration, Diabetes
- Trial name
- CONSTELLATION (NCT02032173)
- Testing
- Ranibizumab 0.5mg
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Hard Lipid Exudates
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
- Trial name
- NCT02448446
- Testing
- ranibizumab 0.3mg
- Where
- 4 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- South Coast Retina Center; Carson, McBeath, Boswell, Inc.